Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triaryl pyrazoline compound inhibits flavivirus RNA replication.

Francesc Puig-Basagoiti1, Mark Tilgner, Brett M Forshey

  • 1Wadsworth Center, New York State Department of Health, Albany, NY 12208, USA.

Antimicrobial Agents and Chemotherapy
|March 30, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A DirectView focus reduction assay for high-throughput quantification of neutralizing antibodies against influenza A and B viruses.

Cell reports methods·2026
Same author

Local genomic epidemiology investigations of SARS-CoV-2 during the early pandemic response: A global systematic review.

Epidemiology and infection·2026
Same author

Development and Characterization of Candidate Vaccine Viruses against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response.

The Journal of infectious diseases·2026
Same author

Nomenclature for Tracking of Genetic Variation of Seasonal Influenza Viruses.

Influenza and other respiratory viruses·2026
Same author

Development of pre-pandemic influenza candidate vaccine viruses for use in vaccine manufacturing.

NPJ vaccines·2026
Same author

Toll-Like Receptor 7/8 Antagonist Promotes Interleukin-10-Mediated Anti-inflammatory Therapy.

ACS pharmacology & translational science·2026

A novel triaryl pyrazoline compound effectively inhibits flavivirus replication by targeting viral RNA synthesis. This broad-spectrum antiviral shows promise for treating infections like West Nile virus and dengue virus.

Area of Science:

  • Virology
  • Medicinal Chemistry
  • Drug Discovery

Background:

  • Flaviviruses, including West Nile virus and dengue virus, pose significant global health threats.
  • Effective antiviral therapies for flavivirus infections remain limited, necessitating the development of novel inhibitors.

Purpose of the Study:

  • To identify and characterize novel inhibitors of flavivirus replication.
  • To elucidate the mechanism of action of a promising antiviral compound.

Main Methods:

  • High-throughput screening of a compound library using a luciferase-expressing West Nile virus infection assay.
  • Antiviral activity testing against various viruses, including flaviviruses, alphaviruses, coronaviruses, and rhabdoviruses.
  • Mode-of-action studies involving viral entry, assembly, translation, and RNA synthesis assays, including dengue virus replicon systems.

Related Experiment Videos

Main Results:

  • A triaryl pyrazoline compound, {[5-(4-chloro-phenyl)-3-thiophen-2-yl-4,5-dihydro-pyrazol-1-yl]-phenyl-methanone}, was identified as a potent inhibitor of West Nile virus.
  • The compound demonstrated broad-spectrum activity against multiple flaviviruses and other RNA viruses, with no detectable cytotoxicity.
  • Mechanism of action studies revealed specific inhibition of viral RNA synthesis, not viral entry or assembly.

Conclusions:

  • Triaryl pyrazoline exhibits significant broad-spectrum antiflavivirus activity by potently inhibiting viral RNA replication.
  • This compound represents a promising lead for the development of new therapeutic agents against flavivirus infections.